Therapeutic | Lutikizumab |
Target 1 | IL1A |
Heavy Chain 1 | EVQLVESGGGVVQPGRSLRLSCSASGFIFSRYDMSWVRQAPGKGLEWVAYISHGGAGTYYPDSVKGRFTISRDNSKNTLFLQMDSLRPEDTGVYFCARGGVTKGYFDVWGQGTPVTVSS |
Light Chain 1 | DIQMTQSPSSLSASVGDRVTITCRASGNIHNYLTWYQQTPGKAPKLLIYNAKTLADGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQHFWSIPYTFGQGTKLQIT |
100% seqID Fv 1 Structure | None |
99% seqID Fv 1 Structure | None |
95-98% seqID Fv 1 Structure | None |
Target 2 | IL1B |
Heavy Chain 2 | QVQLVESGGGVVQPGRSLRLSCTASGFTFSMFGVHWVRQAPGKGLEWVAAVSYDGSNKYYAESVKGRFTISRDNSKNILFLQMDSLRLEDTAVYYCARGRPKVVIPAPLAHWGQGTLVTFSS |
Light Chain 2 | DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYEASNLETGVPSRFSGSGSGSDFTLTISSLQPEDFATYYCQQTSSFLLSFGGGTKVEHK |
100% seqID Fv 2 Structure | None |
99% seqID Fv 2 Structure | None |
95-98% seqID Fv 2 Structure | None |
Follow these links to our prediction tools:
Format | Bispecific Dual Variable Domain IG |
Isotype | G1;G1 |
Highest Clinical Trial (Aug '23) | Phase-II |
Estimated Status (Aug '23) | Discontinued |
Recorded Developmental Technology | Dual Variable Domain Immunoglobulin Technology |
INN Year Proposed | 2016 |
INN Year Recommended | 2017 |
Companies Involved | Abbott Laboratories, AbbVie |
Conditions Approved | na |
Conditions Active | na |
Conditions Discontinued | Osteoarthritis |
Notes |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]